Key points are not available for this paper at this time.
Background. Antibody to influenza virus hemagglutinin has been traditionally associated with protection. Questions have been raised about its use as a surrogate for vaccine efficacy, particularly with regard to an absolute titer indicating seroprotection.
Ohmit et al. (2011) studied this question.